文献速递浆细胞疾病

RUNX蛋白通过保护IKZF免受降解使多发性骨髓瘤对来那度胺不敏感

RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation.
PubMed 文献 · Leukemia · 2019-02-13

本研究通过质谱筛选发现RUNX1和RUNX3与IKZF1和IKZF3相互作用,该相互作用抑制来那度胺诱导的CRBN依赖性泛素化和降解。通过遗传敲除或小分子AI-10-104抑制RUNX,可使骨髓瘤细胞系和原代肿瘤对来那度胺增敏。

要点

  • RUNX1和RUNX3与IKZF1和IKZF3相互作用,抑制来那度胺诱导的CRBN依赖性降解。
  • 遗传敲除或小分子AI-10-104抑制RUNX可使骨髓瘤细胞对来那度胺增敏。
  • RUNX抑制为增强IMiDs治疗多发性骨髓瘤提供了治疗机会。

核心结论

  • 抑制RUNX可增强IMiDs对多发性骨髓瘤的治疗效果。

研究设计与样本

  • 基于质谱的无偏筛选,鉴定IKZF1和IKZF3的相互作用蛋白。
  • 使用骨髓瘤细胞系和原代肿瘤进行功能验证。

主要发现

  • RUNX1和RUNX3被鉴定为IKZF1和IKZF3的相互作用蛋白。
  • 与RUNX1和RUNX3的相互作用抑制来那度胺诱导的CRBN依赖性结合、泛素化和IKZF1/IKZF3降解。
  • 通过遗传敲除或小分子AI-10-104抑制RUNX,使骨髓瘤细胞系和原代肿瘤对来那度胺增敏。

临床怎么用

  • 作者认为RUNX抑制是增强IMiDs治疗多发性骨髓瘤的有价值治疗机会。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Ikaros family zinc finger protein 1 and 3 (IKZF1 and IKZF3) are transcription factors that promote multiple myeloma (MM) proliferation. The immunomodulatory imide drug (IMiD) lenalidomide promotes myeloma cell death via Cereblon (CRBN)-dependent ubiquitylation and proteasome-dependent degradation of IKZF1 and IKZF3. Although IMiDs have been used as first-line drugs for MM, the overall survival of refractory MM patients remains poor and demands the identification of novel agents to potentiate the therapeutic effect of IMiDs. Using an unbiased screen based on mass spectrometry, we identified the Runt-related transcription factor 1 and 3 (RUNX1 and RUNX3) as interactors of IKZF1 and IKZF3. Interaction with RUNX1 and RUNX3 inhibits CRBN-dependent binding, ubiquitylation, and degradation of IKZF1 and IKZF3 upon lenalidomide treatment. Inhibition of RUNXs, via genetic ablation or a small molecule (AI-10-104), results in sensitization of myeloma cell lines and primary tumors to lenalidomide. Thus, RUNX inhibition represents a valuable therapeutic opportunity to potentiate IMiDs therapy for the treatment of multiple myeloma.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Zhou N, Gutierrez-Uzquiza A, Zheng XY, et al. RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation. Leukemia. 2019. PMID: 30760870. doi:10.1038/s41375-019-0403-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。